Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis

Blood

Volumn 129, Issue 15, 2017, Pages 2161-2171

  Sun, Junjiang ^a   Hua, Baolai ^b   Livingston, Eric W ^c   Taves, Sarah ^c,d   Johansen, Peter B ^d   Hoffman, Maureane ^e   Ezban, Mirella ^d   Monroe, Dougald M ^a   Bateman, Ted A ^a,c   Monahan, Paul E ^a,c,f  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NOVO NORDISK A S   (Denmark)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CARTILAGE; CELL MIGRATION; CELL PROLIFERATION; CHONDROCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; HEMARTHROSIS; HEMOPHILIA B; HISTOPATHOLOGY; HUMAN; JOINT CAPSULE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INJURY; SYNOVIAL FLUID; SYNOVIUM; THROMBOCYTE POOR PLASMA; TREATMENT RESPONSE; WOUND HEALING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; INJURIES; JOINT; KNOCKOUT MOUSE; METABOLISM; SKIN;

ANIMALS; DISEASE MODELS, ANIMAL; FACTOR IX; HEMARTHROSIS; HEMOPHILIA B; JOINTS; MICE; MICE, KNOCKOUT; SKIN; WOUND HEALING;

EID: 85021389330     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-08-734053     Document Type: Article

References (52)

1. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol. 2008;143(5):632-640.
2. Hooiveld MJ, Roosendaal G, Jacobs KM, et al. Initiation of degenerative joint damage by experimental bleeding combined with loading of the joint: a possible mechanism of hemophilic arthropathy. Arthritis Rheum. 2004;50(6): 2024-2031.
3. Boettger MK, Krucker S, Gajda M, Schaible HG, Hilberg T. Repeated autologous intraarticular blood injections as an animal model for joint pain in haemophilic arthropathy. Arthritis Res Ther. 2013; 15(5):R148.
4. Hooiveld M, Roosendaal G, Vianen M, van den Berg M, Bijlsma J, Lafeber F. Blood-induced joint damage: longterm effects in vitro and in vivo. J Rheumatol. 2003;30(2): 339-344.
5. Monroe DM, Mackman N, Hoffman M. Wound healing in hemophilia B mice and low tissue factor mice. Thromb Res. 2010;125(suppl 1):S74-S77.
6. Hoffman M, Harger A, Lenkowski A, Hedner U, Roberts HR, Monroe DM. Cutaneous wound healing is impaired in hemophilia B. Blood. 2006; 108(9):3053-3060.
7. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia. 2008;14(4):804-809.
8. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood. 2008; 112(12):4532-4541.
9. Narkbunnam N, Sun J, Hu G, et al. IL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophilia. J Thromb Haemost. 2013;11(5):881-893.
10. Sen D, Chapla A, Walter N, Daniel V, Srivastava A, Jayandharan GR. Nuclear factor (NF)-κB and its associated pathways are major molecular regulators of blood-induced joint damage in a murine model of hemophilia. J Thromb Haemost. 2013;11(2):293-306.
11. Øvlisen K, Kristensen AT, Valentino LA, Hakobyan N, Ingerslev J, Tranholm M. Hemostatic effect of recombinant factor VIIa, NN1731 and recombinant factor VIII on needle-induced joint bleeding in hemophilia A mice. J Thromb Haemost. 2008;6(6):969-975.
12. Øvlisen K, Kristensen AT, Jensen AL, Tranholm M. IL-1 beta, IL-6, KC and MCP-1 are elevated in synovial fluid from haemophilic mice with experimentally induced haemarthrosis. Haemophilia. 2009;15(3):802-810.
13. Nieuwenhuizen L, Roosendaal G, Coeleveld K, et al. Haemarthrosis stimulates the synovial fibrinolytic system in haemophilic mice. Thromb Haemost. 2013;110(1):173-183.
14. van Meegeren ME, Roosendaal G, Coeleveld K, Nieuwenhuizen L, Mastbergen SC, Lafeber FP. A single intra-articular injection with IL-4 plus IL-10 ameliorates blood-induced cartilage degeneration in haemophilic mice. Br J Haematol. 2013;160(4):515-520.
15. Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther. 2015;26(2):69-81.
16. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
17. Srivastava A. Haemophilia care - beyond the treatment guidelines. Haemophilia. 2014;20(suppl 4):4-10.
18. Negrier C, Young G, Abdul Karim F, et al; paradigm™ 2 and 4 Investigators. Recombinant long-acting glycoPEGylated factor IX (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia. 2016;22(4):507-513.
19. Young G, Collins PW, Colberg T, et al. Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigm™4). Thromb Res. 2016; 141:69-76.
20. Negrier C, Knobe K, Tiede A, Giangrande P, Møss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood. 2011;118(10):2695-2701.
21. Collins PW, Young G, Knobe K, et al; paradigm 2 Investigators. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014;124(26):3880-3886.
22. Østergaard H, Bjelke JR, Hansen L, et al. Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide. Blood. 2011;118(8):2333-2341.
23. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood. 1997;90(10):3962-3966.
24. Jin DY, Zhang TP, Gui T, Stafford DW, Monahan PE. Creation of a mouse expressing defective human factor IX. Blood. 2004;104(6):1733-1739.
25. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia. 2006;12(6):654-662.
26. Lau AG, Sun J, Hannah WB, et al. Joint bleeding in factor VIII deficient mice causes an acute loss of trabecular bone and calcification of joint soft tissues which is prevented with aggressive factor replacement. Haemophilia. 2014;20(5):716-722.
27. McDonald A, Hoffman M, Hedner U, Roberts HR, Monroe DM. Restoring hemostatic thrombin generation at the time of cutaneous wounding does not normalize healing in hemophilia B. J Thromb Haemost. 2007;5(8):1577-1583.
28. Monroe DM, Hoffman M, Roberts HR, Hedner U. Progressive improvement in wound healing with increased therapy in haemophilia B mice. Haemophilia. 2013;19(6):926-932.
29. Bhat V, Olmer M, Joshi S, et al. Vascular remodeling underlies rebleeding in hemophilic arthropathy. Am J Hematol. 2015;90(11): 1027-1035.
30. Liel MS, Greenberg DL, Recht M, Vanek C, Klein RF, Taylor JA. Decreased bone density and bone strength in a mouse model of severe factor VIII deficiency. Br J Haematol. 2012;158(1):140-143.
31. Recht M, Liel MS, Turner RT, Klein RF, Taylor JA. The bone disease associated with factor VIII deficiency in mice is secondary to increased bone resorption. Haemophilia. 2013;19(6):908-912.
32. Kempton CL, Antun A, Antoniucci DM, et al. Bone density in haemophilia: a single institutional cross-sectional study. Haemophilia. 2014;20(1): 121-128.
33. Gerstner G, Damiano ML, Tom A, et al. Prevalence and risk factors associated with decreased bone mineral density in patients with haemophilia. Haemophilia. 2009;15(2):559-565.
34. Khawaji M, Akesson K, Berntorp E. Long-term prophylaxis in severe haemophilia seems to preserve bone mineral density. Haemophilia. 2009;15(1):261-266.
35. Soucek O, Komrska V, Hlavka Z, et al. Boys with haemophilia have low trabecular bone mineral density and sarcopenia, but normal bone strength at the radius. Haemophilia. 2012;18(2):222-228.
36. Barnes C, Wong P, Egan B, et al. Reduced bone density among children with severe hemophilia. Pediatrics. 2004;114(2):e177-e181.
37. Wells AJ, McLaughlin P, Simmonds JV, et al. A case-control study assessing bone mineral density in severe haemophilia A in the UK. Haemophilia. 2015;21(1):109-115.
38. Mansouritorghabeh H, Rezaieyazdi Z, Saadati N, Saghafi M, Mirfeizi Z, Rezai J. Reduced bone density in individuals with severe hemophilia B. Int J Rheum Dis. 2009;12(2):125-129.
39. Lee A, Boyd SK, Kline G, Poon MC. Premature changes in trabecular and cortical microarchitecture result in decreased bone strength in hemophilia. Blood. 2015;125(13): 2160-2163.
40. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM. Canine hemophilia; observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med. 1949;90(2): 97-111.
41. Swanton MC. Hemophilic arthropathy in dogs. Lab Invest. 1959;8:1269-1277.
42. Sørensen KR, Roepstorff K, Wiinberg B, et al. The F8(-/-) rat as a model of hemophilic arthropathy. J Thromb Haemost. 2016;14(6):1216-1225.
43. Carney DH, Mann R, Redin WR, et al. Enhancement of incisional wound healing and neovascularization in normal rats by thrombin and synthetic thrombin receptor-activating peptides. J Clin Invest. 1992;89(5):1469-1477.
44. Jackson CJ, Xue M, Thompson P, et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen. 2005;13(3): 284-294.
45. Julovi SM, Xue M, Dervish S, Sambrook PN, March L, Jackson CJ. Protease activated receptor-2 mediates activated protein C-induced cutaneous wound healing via inhibition of p38. Am J Pathol. 2011;179(5):2233-2242.
46. Pagel CN, de Niese MR, Abraham LA, et al. Inhibition of osteoblast apoptosis by thrombin. Bone. 2003;33(4):733-743.
47. Pagel CN, Song SJ, Loh LH, et al. Thrombin-stimulated growth factor and cytokine expression in osteoblasts is mediated by protease-activated receptor-1 and prostanoids. Bone. 2009;44(5): 813-821.
48. Kurata T, Hayashi T, Yoshikawa T, et al. Activated protein C stimulates osteoblast proliferation via endothelial protein C receptor. Thromb Res. 2010; 125(2):184-191.
49. Shen K, Murphy CM, Chan B, et al. Activated protein C (APC) can increase bone anabolism via a protease-activated receptor (PAR)1/2 dependent mechanism. J Orthop Res. 2014; 32(12):1549-1556.
50. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol. 2006;26(11): 2445-2453.
51. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost. 2001;86(4):1035-1039.
52. Wong JM, Mann HA, Goddard NJ. Perioperative clotting factor replacement and infection in total knee arthroplasty. Haemophilia. 2012;18(4): 607-612.